LRRK2 levels in immune cells are increased in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Mutations associated with leucine-rich repeat kinase 2 are the most common known cause of Parkinson’s disease. The known expression of leucine-rich repeat kinase 2 in immune cells and its negative regulatory function of nuclear factor of activated T cells implicates leucine-rich repeat kinase 2 in the development of the inflammatory environment characteristic of Parkinson’s disease. The aim of this study was to determine the expression pattern of leucine-rich repeat kinase 2 in immune cell subsets and correlate it with the immunophenotype of cells from Parkinson’s disease and healthy subjects. For immunophenotyping, blood cells from 40 Parkinson’s disease patients and 32 age and environment matched-healthy control subjects were analyzed by flow cytometry. Multiplexed immunoassays were used to measure cytokine output of stimulated cells. Leucine-rich repeat kinase 2 expression was increased in B cells ( p = 0.0095), T cells ( p = 0.029), and CD16 + monocytes ( p = 0.01) of Parkinson’s disease patients compared to healthy controls. Leucine-rich repeat kinase 2 induction was also increased in monocytes and dividing T cells in Parkinson’s disease patients compared to healthy controls. In addition, Parkinson’s disease patient monocytes secreted more inflammatory cytokines compared to healthy control, and cytokine expression positively correlated with leucine-rich repeat kinase 2 expression in T cells from Parkinson’s disease but not healthy controls. Finally, the regulatory surface protein that limits T-cell activation signals, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), was decreased in Parkinson’s disease compared to HC in T cells ( p = 0.029). In sum, these findings suggest that leucine-rich repeat kinase 2 has a regulatory role in immune cells and Parkinson’s disease. Functionally, the positive correlations between leucine-rich repeat kinase 2 expression levels in T-cell subsets, cytokine expression and secretion, and T-cell activation states suggest that targeting leucine-rich repeat kinase 2 with therapeutic interventions could have direct effects on immune cell function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593 · cited 1×
“24,25 LRRK2 is also a member of the receptor interacting protein kinase family, which are proteins that detect and respond to cellular stress by regulating cell death and activation of the immune system.”
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405 · cited 1×
“1,2 Mutations have also been found in sporadic cases at rates varying from 0.3–41% depending on the country of origin and ethnicity of the population studied.”
InfluentialAntigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926 · cited 1×
“40 To investigate the hypothesis that LRRK2 expression affects cytokine production, we used intracellular cytokine staining (ICS) to measure cytokine expression in a cell type-specific manner as well as multiplexed immunoassays to measure cytokine secretion into the culture media.”
Debris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111
The CD14+ CD16+ blood monocytes: their role in infection and inflammation
Ziegler-Heitbrock, L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806510 · Cited by 1,041 · cited 1×
“42 Therefore, the fi nding that LRRK2 levels are notably increased in CD16 + monocytes of PD patients may have functional relevance to disease risk or progression given that it was recently reported that IFN-γ induces more LRRK2 in this subset of monocytes compared to classical CD16 — monocytes.”
BackgroundGenomewide Association Study of Leprosy
Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y., Cui, Y., Yan, X.-X., Yang, H.-T., Yang, R.-D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903753 · Cited by 1,031
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1
Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002) · Annals of Neurology · doi:10.1002/ana.10113 · Cited by 667 · cited 2×
“6,7 Given the multiple, highly diverse enzymatic and protein interacting domains, it is likely that LRRK2 may have different binding partners in different cell types.”
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells
Plowey, E. D., Cherra, S. J., Liu, Y., & Chu, C. T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05217.x · Cited by 493
LRRK2 in Parkinson's disease: protein domains and functional insights
Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., & Gallo, K. A. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.03.006 · Cited by 489
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463 · cited 2×
“…vs. HC subjects There are several reports indicating that LRRK2 expression in immune cells increases following in fl ammatory stimuli such as IFN-γ or microbial components like LPS. 22, 23, 30, 38 We sought to replicate these data in monocytes and explore whether this paradigm held true in T cells.”
BackgroundSelf-citationCharacterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.538 · Cited by 417 · cited 1×
“28 However, due to the reported off-target effects of LRRK2-IN1, specifically ERK5 inhibition, 44 it is possible that this decrease cannot be attributed wholly to LRRK2 kinase activity.”
LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens
Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., Korzenik, J. R., Rioux, J. D., Daly, M. J., Xavier, R. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000548 · Cited by 415
Chardin, P., & McCormick, F. (1999) · Cell · doi:10.1016/s0092-8674(00)80724-2 · Cited by 407
Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405
The RIP kinases: crucial integrators of cellular stress
Meylan, E., & Tschopp, J. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.01.003 · Cited by 382 · cited 2×
“26,27 Pro-inflammatory Pro-inflammatory signals, such as interferon-γ (IFN-γ ), 23,28,29 lipopolysaccharide (LPS), 22,30 and interleukin (IL)-1 β have been shown to increase LRRK2 expression.”
Liu, Z., Lee, J., Krummey, S., Lu, W., Cai, H., & Lenardo, M. J. (2011) · Nature Immunology · doi:10.1038/ni.2113 · Cited by 361 · cited 2×
“Given the established role of LRRK2 as a potential negative regulator of NFAT, 16 the differences we observed between PD patients and HC subjects suggest that LRRK2 may be important in the regulation of both innate and adaptive immune cells within the context of PD.”
BackgroundCD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease
Saunders, J. A. H., Estes, K. A., Kosloski, L. M., Allen, H. E., Dempsey, K. M., Torres-Russotto, D. R., Meza, J. L., Santamaria, P. M., Bertoni, J. M., Murman, D. L., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9402-z · Cited by 323 · cited 1×
“Consistent with what has been previously reported, it appears that this decrease is due strictly to the CD4 + subset and not to CD8 + T-cell frequencies 37 (Supplementary Fig.”
ResultAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysis
Gagne, J. J., & Power, M. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5a4a3 · Cited by 322
Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons
Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R., Anisman, H., Hayley, S., & Park, D. S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 315
Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients
Grozdanov, V., Bliederhaeuser, C., Ruf, W. P., Roth, V., Fundel-Clemens, K., Zondler, L., Brenner, D., Martin-Villalba, A., Hengerer, B., Kassubek, J., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1345-4 · Cited by 295 · cited 1×
“43 The monocyte data taken together with the increased LRRK2 expression in T cells and B cells suggest that following an inflammatory challenge, individuals with PD will mount an exacerbated inflammatory response compared to healthy individuals that could lead to sustained immune activation and…”
Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R. F., Tong, Y., Kabbach, G., Venderova, K., Girardin, S. E., Bulman, D. E., Scherzer, C. R., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0653-2 · Cited by 283 · cited 5×
“22,28 To date, the most commonly used approach to ascertain LRRK2 expression levels has been western blotting and quantitative reverse transcriptase-polymerase chain reaction.”
InfluentialLeucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions
Greggio, E., & Cookson, M. R. (2009) · ASN Neuro · doi:10.1042/an20090007 · Cited by 272
Perera, G., Ranola, M., Rowe, D. B., Halliday, G. M., & Dzamko, N. (2016) · Scientific Reports · doi:10.1038/srep31391 · Cited by 259 · cited 1×
“31 Recently, it was reported that increased expression of LRRK2 in monocytes following IFN-γ stimulation occurs via a mechanism involving extracellular signal-related kinase 5 (ERK5) signaling.”
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy
Schapansky, J., Nardozzi, J. D., Felizia, F., & LaVoie, M. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu138 · Cited by 226
Smoking duration, intensity, and risk of Parkinson disease
Chen, H., Huang, X., Guo, X., Mailman, R. B., Park, Y., Kamel, F., Umbach, D. M., Xu, Q., Hollenbeck, A., Schatzkin, A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d55f38 · Cited by 223
Gillardon, F., Schmid, R., & Draheim, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.001 · Cited by 222 · cited 1×
“…vs. HC subjects There are several reports indicating that LRRK2 expression in immune cells increases following in fl ammatory stimuli such as IFN-γ or microbial components like LPS. 22, 23, 30, 38 We sought to replicate these data in monocytes and explore whether this paradigm held true in T cells.”
BackgroundGuo, L., Gandhi, P. N., Wang, W., Petersen, R. B., Wilson-Delfosse, A. L., & Chen, S. G. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.07.007 · Cited by 208 · cited 1×
“6,7 Enzymatic domains include a ROC (Ras of complex) GTPase domain 8 and a serine/threonine kinase domain.”
Receptor-interacting protein (RIP) kinase family
Zhang, D., Lin, J., & Han, J. (2010) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.10 · Cited by 199 · cited 2×
“26,27 Pro-inflammatory Pro-inflammatory signals, such as interferon-γ (IFN-γ ), 23,28,29 lipopolysaccharide (LPS), 22,30 and interleukin (IL)-1 β have been shown to increase LRRK2 expression.”
Clinical features of LRRK2‐associated Parkinson's disease in central Norway
Aasly, J. O., Toft, M., Fernandez‐Mata, I., Kachergus, J., Hulihan, M., White, L. R., & Farrer, M. (2005) · Annals of Neurology · doi:10.1002/ana.20456 · Cited by 191
Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte Maturation
Thévenet, J., Pescini Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C., & Sagot, Y. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021519 · Cited by 189 · cited 8×
“23,28,29 Also, IFN-γ stimulation was shown to increase LRRK2 mRNA and protein expression in the non-classical CD14 + CD16 + monocyte population.”
InfluentialLRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
Russo, I., Bubacco, L., & Greggio, E. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-52 · Cited by 178 · cited 8×
“Given that increased inflammation in the periphery and the brain has been associated with the pathophysiology of PD, 32–36 it is possible that LRRK2 may play a role in this process and serve as a regulator of inflammatory and immune responses that influence risk for age-related degeneration and risk for PD. Based on t…”
InfluentialLrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease
Haugarvoll, K., Rademakers, R., Kachergus, J. M., Nuytemans, K., Ross, O. A., Gibson, J. M., Tan, E.-K., Gaig, C., Tolosa, E., Goldwurm, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304044.22253.03 · Cited by 153 · cited 1×
“3 Due to similarities in the clinical presentation of LRRK2-associated PD and idiopathic PD, 3–5 the study of LRRK2 function has the potential to offer new insight into the mechanisms underlying sporadic PD etiology.”
Kannarkat, G. T., Cook, D. A., Lee, J.-K., Chang, J., Chung, J., Sandy, E., Paul, K. C., Ritz, B., Bronstein, J., Factor, S. A., et al. (2015) · npj Parkinson's Disease · doi:10.1038/npjparkd.2015.2 · Cited by 141 · cited 8×
“In addition, recent studies suggest that antigen presentation is altered in a subset of individuals with PD in association with a non-coding SNP (rs 3129882) in the MHC-II locus that synergizes with environmental exposures to increase risk for PD. 45 Although the LRRK2 and MHC-II loci are encoded on different chromoso…”
InfluentialSelf-citationInduction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter
Gibson, H. M., Hedgcock, C. J., Aufiero, B. M., Wilson, A. J., Hafner, M. S., Tsokos, G. C., & Wong, H. K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3831 · Cited by 113 · cited 1×
“46 Therefore, our findings suggest that in healthy individuals LRRK2 is a negative regulator of T-cell activation.”
Gilsbach, B. K., Ho, F. Y., Vetter, I. R., Haastert, P. J. M. V., Wittinghofer, A., & Kortholt, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203223109 · Cited by 113 · cited 1×
“9 There are also multiple protein-interacting domains, including a leucine-rich repeat domain, a C-terminal WD40 repeat domain, and armadillo and ankyrin repeat domains.”
LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6
Berwick, D. C., & Harvey, K. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds342 · Cited by 103
The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease
Rideout, H. J., & Stefanis, L. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1073-5 · Cited by 90
Genetics of Parkinson's disease: LRRK2 on the rise
Brice, A. (2005) · Brain · doi:10.1093/brain/awh676 · Cited by 90 · cited 1×
“12–17 Multiple mutations and normal genetic variations in the LRRK2 gene have been associated with disease.(18) The six most common pathogenic mutations in LRRK2 associated with PD(19) reside in the GTPase and kinase domains.”
mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1
Manzoni, C., Mamais, A., Roosen, D. A., Dihanich, S., Soutar, M. P. M., Plun-Favreau, H., Bandopadhyay, R., Hardy, J., Tooze, S. A., Cookson, M. R., et al. (2016) · Scientific Reports · doi:10.1038/srep35106 · Cited by 83
Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression
Waldburger, J., Masternak, K., Muhlethaler‐Mottet, A., Villard, J., Peretti, M., Landmann, S., & Reith, W. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17813.x · Cited by 81 · cited 1×
“39 To determine if there were any alterations in antigen presentation in patients with PD, we assessed expression levels of HLA-DR and -DQ.”
The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews
Thaler, A., Ash, E. L., Gan‐Or, Z., Orr‐Urtreger, A., & Giladi, N. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0303-0 · Cited by 78 · cited 1×
“3 Due to similarities in the clinical presentation of LRRK2-associated PD and idiopathic PD, 3–5 the study of LRRK2 function has the potential to offer new insight into the mechanisms underlying sporadic PD etiology.”
Kuss, M., Adamopoulou, E., & Kahle, P. J. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12668 · Cited by 72
Rudenko, I. N., & Cookson, M. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0284-z · Cited by 61
LRRK2 deficiency impacts ceramide metabolism in brain
Ferrazza, R., Cogo, S., Melrose, H., Bubacco, L., Greggio, E., Guella, G., Civiero, L., & Plotegher, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.082 · Cited by 60
Pradhan, S., & Andreasson, K. I. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.008 · Cited by 49
The Role of LRRK2 in the Regulation of Monocyte Adhesion to Endothelial Cells
Hongge, L., Kexin, G., Xiaojie, M., Nian, X., & Jinsha, H. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0312-9 · Cited by 36
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“In addition, for sporadic PD patients without LRRK2 mutations, the expression of LRRK2 was found to be increased in immune cells.(259) Infection of G2019S carrying mouse with reovirus leads to elevated ROS production and α-synuclein concentration in the brain compared with noncarriers, probably through modulating infl…”
BackgroundInflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Self-citationInflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Parkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457
Self-citationLRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Metadata
- Authors
- Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., & Tansey, M. G.
- Affiliations
- Emory University (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Tansey, M. G.
- Venue
- npj Parkinson's Disease
- Published
- 2017-03-28
- Volume
- 3
- Issue
- 1
- Pages
- 11-11
- ISSN
- 2373-8057 (ISSN-L)
- PMC
- PMC5459798
- OpenAlex
- W2602156859
- Cited by
- 279
- References
- 53
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 34 · 2023: 33 · 2022: 50 · 2021: 37 · 2020: 27 · 2019: 29 · 2018: 19 · 2017: 3
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Parkinson s Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Emory University (UL1TR000454)
- Parkinson's Foundation
- National Institutes of Health (UL1TR000454)
- School of Medicine, Emory University (UL1TR000454)
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases (T32AI007610)
- National Institute of Neurological Disorders and Stroke (F31NS081830, R21NS084647, F31NS098673, R01NS064934)
- National Institute of Environmental Health Sciences (T32ES012870)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- LRRK2, Parkinson's disease, immune cells, T cells, B cells, monocytes, CTLA-4, inflammatory cytokines, neuroinflammation, T cell activation, immunophenotyping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.